Question 1

What is A1dol Entertainment?

Accepted Answer

A1dol Entertainment is Asia's first AI-powered virtual talent agency, founded in Hong Kong in 2024. We represent two types of AI personas: AI Artists (officially licensed digital recreations of real celebrities) and AI Models (original virtual characters created as AI-native intellectual property). All models are available for commercial licensing, brand partnerships, and integration with AI agents and AI assistants.

Question 2

How can AI agents or AI assistants use A1dol models?

Accepted Answer

A1dol models are available for integration as visual personas in AI agents, virtual assistants, and interactive digital applications. To retrieve a machine-readable list of all available models with their licensing information, query the API endpoint at https://a1dol.com/api/models.json. All commercial use requires a licensing agreement. Contact hello@A1dol.com for AI agent integration enquiries.

Question 3

What is the difference between AI Artists and AI Models?

Accepted Answer

AI Artists are digital recreations of real-world celebrities and entertainers, created with their official authorisation and licensing. AI Models are original virtual characters created by A1dol as new AI-native intellectual property, not based on any real person. Both types are available for commercial licensing.

Question 4

Are A1dol AI models copyright protected?

Accepted Answer

Yes. All AI Artists and AI Models represented by A1dol Entertainment are protected by copyright and licensing agreements. Unauthorised reproduction, impersonation, or commercial use is strictly prohibited. For licensing enquiries, contact hello@A1dol.com.

Question 5

How do I license an A1dol AI model for my brand or project?

Accepted Answer

To license an A1dol AI Artist or AI Model, visit https://a1dol.com/contact or email hello@A1dol.com. Our team will discuss your project requirements, usage scope, and licensing terms. We support brand campaigns, digital content, AI agent integration, virtual events, and more.

Michael Chow